Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Alnylam Pharmaceuticals Inc Market Cap
The Alnylam Pharmaceuticals Inc (ALNY) share price is expected to increase by 37.1% over the next year. This is based on calculating the average 12-month share price estimate provided by 19 stock analysts who have covered ALNY. Price targets range from $135.00 at the low end to $395.00 at the high end. The current analyst consensus for ALNY is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 19 Wall Street analysts have assigned ALNY 14 buy ratings, 5 hold ratings, and 0 sell ratings. This means that analysts expect Alnylam Pharmaceuticals Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ALNY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| luca issi RBC Capital | Buy | $235.0 | maintained | Feb 20, 2024 |
| leland gershell Oppenheimer | Hold | None | maintained | Feb 16, 2024 |
| david lebovitz Citi | Buy | $227.0 | maintained | Feb 16, 2024 |
| keay nakae Chardan Capital | Buy | $225.0 | maintained | Feb 16, 2024 |
| tazeen ahmad Bank of America Securities | Buy | $246.0 | reiterated | Feb 16, 2024 |
| ritu baral TD Cowen | Buy | $260.0 | maintained | Feb 15, 2024 |
| gena wang Barclays | Buy | $236.0 | maintained | Feb 15, 2024 |
| joseph stringer Needham | Buy | $200.0 | maintained | Feb 15, 2024 |
| salveen richter Goldman Sachs | Hold | $173.0 | downgraded | Feb 15, 2024 |
| tiago fauth Wells Fargo | Hold | $161.0 | maintained | Feb 15, 2024 |
| andy chen Wolfe Research | Hold | None | initiatedcoverage | Feb 14, 2024 |
| olivia brayer Cantor Fitzgerald | Hold | $165.0 | initiatedcoverage | Feb 12, 2024 |
| anupam rama J.P. Morgan | Hold | $170.0 | maintained | Feb 1, 2024 |
| patrick trucchio H.C. Wainwright | Buy | $395.0 | reiterated | Jan 31, 2024 |
| kostas biliouris BMO Capital | Buy | $234.0 | rated | Jan 29, 2024 |
| edward tenthoff Piper Sandler | Buy | $217.0 | reiterated | Jan 8, 2024 |
| mani foroohar Leerink Partners | Hold | $135.0 | reiterated | Jan 8, 2024 |
| paul matteis Stifel Nicolaus | Buy | $215.0 | reiterated | Jan 8, 2024 |
| william pickering Bernstein | Buy | $220.0 | maintained | Jan 2, 2024 |
| whitney ijem Canaccord Genuity | Buy | $284.0 | maintained | Dec 14, 2023 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
When did it IPO
2004
Staff Count
2,100
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Yvonne L. Greenstreet M.B.A., MBChB
Market Cap
$19.49B
In 2023, ALNY generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ALNY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
$63.88
LPLA-USD
$257.66
DKNG-USD
$40.75
$80.04
ENTG-USD
$134.34
EXPE-USD
$134.64
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
